18^th Global Ophthalmology, Optometry and Glaucoma Conference

Future of glaucoma treatment and management

Various new enhancements for the investigation front suggest the battle against glaucoma is turning. New meds are directly entering the inside, close by better ways to deal with pass on them. There is creating understanding that the inevitable destiny of glaucoma organization will be build more in light of the optic nerve pathway from the retina to the visual cortex, and not so much compelled to upgrading overflowing. EuroTimes explores what glaucoma treatment may look like soon.

Glaucoma sickness can be controlled even with reasonable treatment patients must have general eye examinations. Treatment regularly continues for the patient's lifetime. Yet troublesome, durable treatment is attractive over vision hardship. Conveying IOP is done down to a dimension that isn't inclined to expedite extra optic nerve hurt; this dimension is insinuated as the target weight and is controlled by the ophthalmologist. High IOP may hurt the optic nerve, which can provoke vision mishap. The dimension shifts for each patient, and a patient's target weight may change over an incredible range. For open-edge glaucoma (the most notable sort), the ophthalmologist may prescribe pharmaceutical to bring down IOP. Topical or oral pharmaceuticals, installs (waferlike parts of drug that are set toward the edge of the eye), or eye treatments can be used.